lobbying
BIO's new CEO talks vaccines and China
My colleagues Rachel Cohrs Zhang and John Wilkerson sat down with John Crowley to talk about his role leading the biotech industry's largest trade group.
They discussed how Crowley, a Republican, feels about growing anti-vax sentiment and the Republican party's mistrust of entities like the FDA and NIH. They also talked about the BIOSECURE Act and how he's thinking about members who have ties to China.
Read more.
people moves
Gilead to switch up R&D leadership
Gilead said yesterday that its chief medical officer, Merdad Parsey, will be leaving. He'll stay on until the first quarter of next year as the company looks for a successor.
This change comes as Gilead has struggled to move beyond its core portfolio of HIV medicines and into new areas like oncology. Gilead shares rose yesterday following the announcement, indicating investors' hopes that a new research chief could spur a turnaround in Gilead's R&D efforts.
Read more.
oncology
A drug to expand access to bone marrow transplants
Receiving a bone marrow transplant for blood cancer treatment can be very difficult since patients want to find donors who are a perfect match. A new study suggests that a chemotherapy called cyclophosphamide could make the process of finding a donor easier.
The study found that donors whose bone marrow did not as closely resemble that of the patient's provided similar outcomes as matched donors, so long as patients received cyclophosphamide.
Read more from my colleague Angus Chen.
No comments